Views & Analysis Multiple sclerosis: A patient’s perspective A patient's view of the challenges facing people with multiple sclerosis.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Laquinimod failure is bad news for Teva's MS hopes Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.
News AZ claims another win for Imfinzi in frontline liver cancer AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
